
Keywords: Drug; Response To Therapy; Prognostic Factor; Biomarker; ACT; Active Ulcerative Colitis Trials; ASCA; anti-Saccharomyces cerevisiae antibodies; ASUC; acute severe ulcerative colitis; CI; confidence interval; CRP; C-reactive protein level; CS; corticostero